Ignite Creation Date:
2024-05-05 @ 6:42 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00538811
Status:
COMPLETED
Last Update Posted:
2010-10-27
First Post:
2007-10-02
Brief Title:
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
Sponsor:
Aga Khan University
Organization:
Aga Khan University
Study Overview
Official Title:
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
When administered simultaneously interferon-alpha 2b interferon-gamma result in dramatic antiviral synergyRibavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha Enhancement of immune responses especially those related to type-1 T helper cell activity may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C The aim of the present study is to evaluate the efficacy and safety of a triple regimen a combination treatment with Interferon gamma Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None